AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
- Outstanding scientist and entrepreneur Dr. Madiha Derouazi appointed as new CSO
- Retiring CSO Dr. Marie Kosco-Vilbois will remain as consultant to ensure smooth handover
- Christopher Roberts, Interim Chief Financial Officer, confirmed in role on a permanent basis
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the appointment, as of January 1st, 2024, of Dr. Madiha Derouazi as Chief Scientific Officer and the promotion of Interim Chief Financial Officer Christopher Roberts to Chief Financial Officer. Dr. Derouazi succeeds the former CSO, Dr. Marie Kosco-Vilbois, who is retiring and will remain with AC Immune as an expert consultant in immunology to ensure continuity and a smooth transition.